查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1662812

2030 年微量殘存疾病市場預測：按產品、樣本類型、臨床效用、技術、最終用戶和地區進行的全球分析

Minimal Residual Disease Market Forecasts to 2030 - Global Analysis By Offering (Hematological Malignancies and Solid Tumors), Sample Type, Clinical Utility, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球微量殘存疾病市場預計在 2024 年將達到 19.6 億美元，預計到 2030 年將達到 45.1 億美元，預測期內的複合年成長率為 14.88%。

微量殘存疾病（MRD）是白血病、淋巴瘤和多發性骨髓瘤等血癌的重要標誌。 MRD 可幫助醫生了解治療效果，並協助他們做出未來治療的決策。流式細胞技術、聚合酵素鏈鎖反應(PCR) 和次世代定序(NGS) 等先進技術能夠靈敏地檢測 MRD，從而實現個人化治療調整、早期療育並改善患者的長期預後。此外，MRD 是指治療後仍殘留在患者體內的少量癌細胞，無法透過傳統的影像檢查或實驗室檢測檢測到，但可能導致疾病復發。

根據BD Biosciences介紹，MRD是急性淋巴性白血病和多發性骨髓瘤等血癌臨床檢測的重要生物標記物，敏感性和特異性值通常超過95%。

個性化醫療的傳播

隨著精準腫瘤學變得越來越普及，對 MRD 檢測的需求也日益增加。 MRD 檢測透過準確識別殘留疾病，可以實現個人化治療調整，例如，降低復發風險低患者的治療強度，增加復發風險高患者的治療劑量。這種方法可以改善患者的治療效果，同時減少不必要治療的副作用和經濟負擔。此外，由於 MRD 測試被納入精準醫療框架，市場正在擴大。

昂貴的 MRD 檢測

MRD 檢測的高成本是阻礙其廣泛應用的主要障礙之一。數位 PCR、多參數流式細胞技術和下一代定序 (NGS) 等先進方法成本高昂，因為它們需要專門的設備、化學品和熟練的勞動力。根據所使用的技術和測試的標記數量，每次 MRD 測試的費用從幾百美元到數千美元不等。對於資源不足的衛生系統來說，負擔能力仍然是一個問題，特別是在開發中國家。此外，對接受長期治療的癌症患者進行 MRD 定期監測會進一步增加成本並限制治療機會。

擴大固體癌的 MRD 檢測

儘管微量殘存疾病檢測已廣泛應用於骨髓惡性腫瘤，但在固體癌中的應用仍提供了巨大的成長機會。循環腫瘤DNA (ctDNA) 分析是識別前列腺癌、結腸癌、肺癌和乳腺癌等固體癌中的 MRD 的一種有前途的方法。與傳統成像方法相比，透過 ctDNA 檢測 MRD 可以在腫瘤出現在掃描中之前檢測分子復發，從而實現早期干預。此外，Foundation Medicine、Natera 和 Guardant Health 等公司對固體癌MRD 檢測的投資正在刺激新癌症類型的研究和商業性擴展。

嚴格的監管要求

MRD 測試受到嚴格的監管審查，因為其臨床應用影響重要的癌症治療決策。在核准MRD檢測法之前，歐洲藥品管理局 (EMA)、美國食品藥物管理局(FDA) 等監管機構以及其他國際醫療機構都要求進行徹底的臨床檢驗。監管核准過程漫長且成本高昂，這可能會延遲新產品的推出。此外，由於不同地區法律規範不同，尋求國際企業發展的公司面臨合規挑戰。不遵守不斷變化的監管要求可能會導致產品召回、處罰和市場准入限制。

COVID-19 的影響

COVID-19 疫情以多種方式影響了微小殘留疾病 (MRD) 市場。最初，封鎖和醫療系統負擔過重導致實驗室測試、癌症篩檢和診斷程序被暫停。許多非緊急的癌症監測測試，例如 MRD 評估，已被降低優先順序或推遲，導致測試量減少。然而，這次疫情也激發了人們對非侵入性MRD檢測技術的興趣，例如循環腫瘤DNA (ctDNA) 分析，透過加速遠端監控、液態切片的採用和分散實驗室檢測的發展。此外，疫情爆發後，人們對精準醫療和腫瘤學研究的關注度不斷提高，這也再次證明了 MRD 檢測的重要性，從而帶來了新的投資、監管支持和技術發展，推動了市場擴張。

預測期內，檢測試劑套件和試劑部分預計將達到最大幅度成長。

預計在預測期內，檢測試劑套件和試劑部分將佔據市場佔有率。這些檢測套件和試劑是 MRD 檢測中經常採用的方法所必需的，包括流式細胞技術、聚合酵素鏈鎖反應(PCR) 和下一代定序 (NGS)。它們的重複使用確保了它們在醫院、研究機構和診斷實驗室的持續使用，從而支持它們在市場上繼續佔據主導地位。此外，用於檢測殘留癌細胞痕跡的高靈敏度和特異性試劑的開發進一步推動了該細分市場的成長，成為 MRD 市場的重要收益驅動力。

治療反應評估部分預計在預測期內以最高複合年成長率成長

預計治療反應評估部分在預測期內將呈現最高的成長率。 MRD 檢測在評估免疫療法、標靶治療和化療方案的療效方面的應用日益廣泛，這推動了這個市場的發展。數位 PCR 和次世代定序(NGS) 的發展現在使臨床醫生能夠根據 MRD 狀態即時調整治療方案，從而有可能改善患者的治療效果並減少不必要的治療毒性。此外，監管部門核准MRD 作為臨床試驗和市場開發的生物標記也推動了該市場的成長，加速了其納入癌症治療方案。

比最大的地區

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療基礎設施、精準醫療的高度採用以及對癌症研究的強勁投資。該地區骨髓惡性腫瘤發生率高，診斷實驗室聲譽良好，並且可以輕鬆獲得用於 MRD 檢測的數位 PCR 和次世代定序 (NGS) 等最尖端科技。此外，美國FDA 的支持性法規、使用 MRD 作為生物標記的臨床試驗數量的增加以及製藥和診斷公司之間日益成長的夥伴關係，都有助於北美市場在 MRD 中佔據主導地位。

複合年成長率最高的地區

預計預測期內亞太地區將呈現最高的複合年成長率。這是由於癌症發生率的增加、醫療設施的改善以及尖端診斷工具的使用增加。隨著中國、印度和日本等國家大力投資精準醫療和腫瘤學研究，對 MRD 檢測的需求也隨之增加。此外，政府改善癌症診斷的措施、增加醫療保健支出以及提高對早期癌症檢測的認知也推動了市場的成長。該地區的外國診斷公司和當地醫療保健提供者之間的合作也在增加，預計將提高 MRD 技術的採用和可近性。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球微量殘存疾病市場依產品分類

  • 介紹
  • 檢測套件和試劑
  • 設備/平台
  • 軟體/資料分析解決方案
  • 服務

6. 全球微量殘存疾病市場（依疾病類型）

  • 介紹
  • 造血系統惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
    • 骨髓發育不良症候群(MDS)
  • 固態腫瘤
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 其他

7. 全球微量殘存疾病市場（依樣本類型）

  • 介紹
  • 血
  • 骨髓
  • 其他

8. 全球微量殘存疾病市場（依臨床應用）

  • 介紹
  • MRD監測和檢測
  • 治療反應評估
  • 預後和風險分類

9. 全球微量殘存疾病市場（依技術）

  • 介紹
  • 流式細胞技術
  • 聚合酵素鏈鎖反應（PCR）
    • 定量 PCR (qPCR)
    • 數位 PCR (dPCR)
  • 新一代定序（NGS）
  • 螢光原位雜合反應（FISH）
  • 質譜分析

第 10 章 全球微量殘存疾病市場（依最終用戶）

  • 介紹
  • 醫院和專科診所
  • 診斷實驗室
  • 學術研究所
  • 製藥和生物技術公司
  • 合約研究組織 (CRO)

第 11 章 全球微量殘存疾病市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Adaptive BIoTechnologies Corporation
  • F. Hoffmann-La Roche Ltd
  • Natera Inc.
  • Guardant Health
  • QIAGEN NV
  • Bio-Rad Laboratories Inc.
  • Exact Sciences Corporation
  • Sysmex Corporation
  • NeoGenomics Inc.
  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Techne Corporation
  • Invitae Corporation
  • Invivoscribe Inc.
  • Quest Diagnostics
  • PerkinElmer Inc.
  • Agilent Technologies Inc.
  • Laboratory Corporation of America Holdings
Product Code: SMRC28673

According to Stratistics MRC, the Global Minimal Residual Disease Market is accounted for $1.96 billion in 2024 and is expected to reach $4.51 billion by 2030 growing at a CAGR of 14.88% during the forecast period. Minimal Residual Disease (MRD) is an important marker in hematologic cancers like leukemia, lymphoma, and multiple myeloma. It helps doctors figure out how well treatment is working and make decisions about future care. Advanced techniques like flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) enable highly sensitive detection of MRD, allowing for personalized treatment adjustments, early intervention, and improved long-term patient outcomes. Moreover, MRD is the small number of cancer cells that remain in a patient's body after treatment, which are undetectable through conventional imaging or laboratory tests but can still cause relapse.

According to BD Biosciences, MRD is a crucial biomarker in clinical trials for blood cancers such as acute lymphoblastic leukemia and multiple myeloma, with sensitivity and specificity values often exceeding 95%.

Market Dynamics:

Driver:

Increasing personalized medicine adoption

The need for MRD testing is growing as precision oncology becomes more prevalent. MRD tests enable individualized treatment modifications by precisely identifying residual disease, such as lowering treatment intensity for patients with a low risk of relapse or increasing therapy for high-risk patients. This method reduces the negative effects and financial burden of needless treatments while also improving patient outcomes. Additionally, the market is expanding as a result of MRD testing's incorporation into precision medicine frameworks.

Restraint:

Expensive MRD testing

The high expense of MRD testing is one of the main obstacles preventing its widespread use. Advanced methods like digital PCR, multi-parameter flow cytometry, and next-generation sequencing (NGS) are costly because they call for specialized equipment, chemicals, and skilled workers. Depending on the technology employed and the quantity of markers examined, MRD testing can cost anywhere from hundreds to thousands of dollars per test. Affordability is still a problem for healthcare systems with little funding, especially in developing nations. Furthermore, regular MRD monitoring for cancer patients receiving long-term therapy raises costs even more and restricts access.

Opportunity:

Extension of MRD examination in solid cancers

The use of minimal residual disease (MRD) testing in solid tumors offers a substantial growth opportunity, despite the fact that it has been extensively adopted in hematologic malignancies. A promising method for identifying MRD in solid tumors like prostate, colorectal, lung, and breast cancers is circulating tumor DNA (ctDNA) analysis. In contrast to conventional imaging methods, ctDNA-based MRD detection enables earlier intervention by detecting molecular recurrence before tumors appear on scans. Moreover, research and commercial expansion into new cancer types are being fueled by investments made in MRD assays for solid tumors by companies such as Foundation Medicine, Natera, and Guardant Health.

Threat:

Tough regulatory conditions

MRD testing is subject to strict regulatory oversight, as its clinical applications involve critical cancer treatment decisions. Before approving MRD assays, regulatory bodies like the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and other international health authorities demand thorough clinical validation. The lengthy and expensive regulatory approval process can postpone new products' release onto the market. Additionally, businesses looking to expand internationally face compliance issues due to regional differences in regulatory frameworks. Product recalls, penalties, or limitations on market access may arise from noncompliance with changing regulatory requirements.

Covid-19 Impact:

The COVID-19 pandemic had a mixed effect on the market for minimal residual disease (MRD). At first, lockdowns and overburdened healthcare systems disrupted clinical trials, cancer screenings, and diagnostic procedures. Testing volumes decreased as a result of the deprioritization or delay of numerous non-urgent cancer monitoring tests, such as MRD evaluations. But the pandemic also spurred interest in non-invasive MRD detection techniques like circulating tumor DNA (ctDNA) analysis by speeding up developments in remote monitoring, liquid biopsy adoption, and decentralized clinical trials. Furthermore, the significance of MRD testing has also been reaffirmed by the post-pandemic increased focus on precision medicine and oncology research, which has resulted in new investments, regulatory support, and technological developments that propel market expansion.

The Assay Kits & Reagents segment is expected to be the largest during the forecast period

The Assay Kits & Reagents segment is expected to account for the largest market share during the forecast period. These assay kits and reagents are necessary for methods that are frequently employed in MRD testing, including flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). Their recurrent nature guarantees ongoing use in hospitals, research facilities, and diagnostic labs, supporting their continued market dominance. Moreover, this segment's growth is further fueled by developments in highly sensitive and specific reagents for detecting traces of remaining cancer cells, which makes it a significant source of revenue for the MRD market.

The Treatment Response Assessment segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Treatment Response Assessment segment is predicted to witness the highest growth rate. The growing use of MRD testing to assess the efficacy of immunotherapy's, targeted therapies, and chemotherapy regimens is what is driving this market. Clinicians can now modify treatment in real time based on MRD status thanks to developments in digital PCR and next-generation sequencing (NGS), which enhances patient outcomes and lowers needless treatment toxicity. Additionally, growth in this market is also being fueled by regulatory approvals for MRD as a biomarker in clinical trials and drug development, which is speeding up its incorporation into oncology treatment protocols.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by advanced healthcare infrastructure, high adoption of precision medicine, and strong investments in cancer research. The area benefits from a high incidence of hematologic malignancies, reputable diagnostic labs, and easy access to state-of-the-art technologies like digital PCR for MRD detection and next-generation sequencing (NGS). Furthermore, the U.S. FDA's supportive regulations, the rise in clinical trials using MRD as a biomarker, and the expansion of pharmaceutical and diagnostic company partnerships all contribute to North America's market dominance in MRD.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR because of the increased incidence of cancer, the development of better healthcare facilities, and the growing use of cutting-edge diagnostic tools. The need for MRD testing is being driven by significant investments being made in precision medicine and oncology research by nations like China, India, and Japan. Moreover, the market is also growing faster due to government initiatives to improve cancer diagnostics, rising healthcare spending, and increased awareness of early cancer detection. Increased partnerships between foreign diagnostic firms and regional healthcare providers are also taking place in the area, which will increase MRD technology adoption and accessibility.

Key players in the market

Some of the key players in Minimal Residual Disease market include Adaptive Biotechnologies Corporation, F. Hoffmann-La Roche Ltd, Natera Inc., Guardant Health, QIAGEN N.V., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Sysmex Corporation, NeoGenomics Inc., Illumina Inc., Thermo Fisher Scientific Inc., Bio-Techne Corporation, Invitae Corporation, Invivoscribe Inc., Quest Diagnostics, PerkinElmer Inc., Agilent Technologies Inc. and Laboratory Corporation of America Holdings.

Key Developments:

In February 2025, Bio-Rad Laboratories, Inc launched its TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits. The new kits are designed to offer a convenient method to label any antibody with one of Bio-Rad's StarBright Dyes, for use in either flow cytometry or fluorescent western blot experiments.

In November 2024, Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc., a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Poseida's R&D portfolio includes pre-clinical and clinical-stage off-the-shelf CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms.

In March 2024, Sysmex Corporation and CellaVision AB will be working together to advance hematology solutions by expanding its portfolio, including next-generation cell morphology analyzers. Going forward, the companies will work to further increase efficiency and standardization of the testing workflow in the hematology field, increase the precision of cell morphology classification, and provide value in supporting diagnosis.

Offerings Covered:

  • Assay Kits & Reagents
  • Instruments/Platforms
  • Software/Data Analysis Solutions
  • Services

Disease Types Covered:

  • Hematological Malignancies
  • Solid Tumors

Sample Types Covered:

  • Blood
  • Bone Marrow
  • Other Sample Types

Clinical Utilities Covered:

  • MRD Monitoring & Detection
  • Treatment Response Assessment
  • Prognosis & Risk Stratification

Technologies Covered:

  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • Fluorescence In Situ Hybridization (FISH)
  • Mass Spectrometry

End Users Covered:

  • Hospitals & Specialty Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotech Companies
  • Contract Research Organizations (CROs)

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Minimal Residual Disease Market, By Offering

  • 5.1 Introduction
  • 5.2 Assay Kits & Reagents
  • 5.3 Instruments/Platforms
  • 5.4 Software/Data Analysis Solutions
  • 5.5 Services

6 Global Minimal Residual Disease Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Hematological Malignancies
    • 6.2.1 Leukemia
    • 6.2.2 Lymphoma
    • 6.2.3 Multiple Myeloma
    • 6.2.4 Myelodysplastic Syndromes (MDS)
  • 6.3 Solid Tumors
    • 6.3.1 Breast Cancer
    • 6.3.2 Colorectal Cancer
    • 6.3.3 Lung Cancer
    • 6.3.4 Other Solid Tumors

7 Global Minimal Residual Disease Market, By Sample Type

  • 7.1 Introduction
  • 7.2 Blood
  • 7.3 Bone Marrow
  • 7.4 Other Sample Types

8 Global Minimal Residual Disease Market, By Clinical Utility

  • 8.1 Introduction
  • 8.2 MRD Monitoring & Detection
  • 8.3 Treatment Response Assessment
  • 8.4 Prognosis & Risk Stratification

9 Global Minimal Residual Disease Market, By Technology

  • 9.1 Introduction
  • 9.2 Flow Cytometry
  • 9.3 Polymerase Chain Reaction (PCR)
    • 9.3.1 Quantitative PCR (qPCR)
    • 9.3.2 Digital PCR (dPCR)
  • 9.4 Next Generation Sequencing (NGS)
  • 9.5 Fluorescence In Situ Hybridization (FISH)
  • 9.6 Mass Spectrometry

10 Global Minimal Residual Disease Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & Specialty Clinics
  • 10.3 Diagnostic Laboratories
  • 10.4 Academic & Research Institutes
  • 10.5 Pharmaceutical & Biotech Companies
  • 10.6 Contract Research Organizations (CROs)

11 Global Minimal Residual Disease Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Adaptive Biotechnologies Corporation
  • 13.2 F. Hoffmann-La Roche Ltd
  • 13.3 Natera Inc.
  • 13.4 Guardant Health
  • 13.5 QIAGEN N.V.
  • 13.6 Bio-Rad Laboratories Inc.
  • 13.7 Exact Sciences Corporation
  • 13.8 Sysmex Corporation
  • 13.9 NeoGenomics Inc.
  • 13.10 Illumina Inc.
  • 13.11 Thermo Fisher Scientific Inc.
  • 13.12 Bio-Techne Corporation
  • 13.13 Invitae Corporation
  • 13.14 Invivoscribe Inc.
  • 13.15 Quest Diagnostics
  • 13.16 PerkinElmer Inc.
  • 13.17 Agilent Technologies Inc.
  • 13.18 Laboratory Corporation of America Holdings

List of Tables

  • Table 1 Global Minimal Residual Disease Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Minimal Residual Disease Market Outlook, By Offering (2022-2030) ($MN)
  • Table 3 Global Minimal Residual Disease Market Outlook, By Assay Kits & Reagents (2022-2030) ($MN)
  • Table 4 Global Minimal Residual Disease Market Outlook, By Instruments/Platforms (2022-2030) ($MN)
  • Table 5 Global Minimal Residual Disease Market Outlook, By Software/Data Analysis Solutions (2022-2030) ($MN)
  • Table 6 Global Minimal Residual Disease Market Outlook, By Services (2022-2030) ($MN)
  • Table 7 Global Minimal Residual Disease Market Outlook, By Disease Type (2022-2030) ($MN)
  • Table 8 Global Minimal Residual Disease Market Outlook, By Hematological Malignancies (2022-2030) ($MN)
  • Table 9 Global Minimal Residual Disease Market Outlook, By Leukemia (2022-2030) ($MN)
  • Table 10 Global Minimal Residual Disease Market Outlook, By Lymphoma (2022-2030) ($MN)
  • Table 11 Global Minimal Residual Disease Market Outlook, By Multiple Myeloma (2022-2030) ($MN)
  • Table 12 Global Minimal Residual Disease Market Outlook, By Myelodysplastic Syndromes (MDS) (2022-2030) ($MN)
  • Table 13 Global Minimal Residual Disease Market Outlook, By Solid Tumors (2022-2030) ($MN)
  • Table 14 Global Minimal Residual Disease Market Outlook, By Breast Cancer (2022-2030) ($MN)
  • Table 15 Global Minimal Residual Disease Market Outlook, By Colorectal Cancer (2022-2030) ($MN)
  • Table 16 Global Minimal Residual Disease Market Outlook, By Lung Cancer (2022-2030) ($MN)
  • Table 17 Global Minimal Residual Disease Market Outlook, By Other Solid Tumors (2022-2030) ($MN)
  • Table 18 Global Minimal Residual Disease Market Outlook, By Sample Type (2022-2030) ($MN)
  • Table 19 Global Minimal Residual Disease Market Outlook, By Blood (2022-2030) ($MN)
  • Table 20 Global Minimal Residual Disease Market Outlook, By Bone Marrow (2022-2030) ($MN)
  • Table 21 Global Minimal Residual Disease Market Outlook, By Other Sample Types (2022-2030) ($MN)
  • Table 22 Global Minimal Residual Disease Market Outlook, By Clinical Utility (2022-2030) ($MN)
  • Table 23 Global Minimal Residual Disease Market Outlook, By MRD Monitoring & Detection (2022-2030) ($MN)
  • Table 24 Global Minimal Residual Disease Market Outlook, By Treatment Response Assessment (2022-2030) ($MN)
  • Table 25 Global Minimal Residual Disease Market Outlook, By Prognosis & Risk Stratification (2022-2030) ($MN)
  • Table 26 Global Minimal Residual Disease Market Outlook, By Technology (2022-2030) ($MN)
  • Table 27 Global Minimal Residual Disease Market Outlook, By Flow Cytometry (2022-2030) ($MN)
  • Table 28 Global Minimal Residual Disease Market Outlook, By Polymerase Chain Reaction (PCR) (2022-2030) ($MN)
  • Table 29 Global Minimal Residual Disease Market Outlook, By Quantitative PCR (qPCR) (2022-2030) ($MN)
  • Table 30 Global Minimal Residual Disease Market Outlook, By Digital PCR (dPCR) (2022-2030) ($MN)
  • Table 31 Global Minimal Residual Disease Market Outlook, By Next Generation Sequencing (NGS) (2022-2030) ($MN)
  • Table 32 Global Minimal Residual Disease Market Outlook, By Fluorescence In Situ Hybridization (FISH) (2022-2030) ($MN)
  • Table 33 Global Minimal Residual Disease Market Outlook, By Mass Spectrometry (2022-2030) ($MN)
  • Table 34 Global Minimal Residual Disease Market Outlook, By End User (2022-2030) ($MN)
  • Table 35 Global Minimal Residual Disease Market Outlook, By Hospitals & Specialty Clinics (2022-2030) ($MN)
  • Table 36 Global Minimal Residual Disease Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 37 Global Minimal Residual Disease Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 38 Global Minimal Residual Disease Market Outlook, By Pharmaceutical & Biotech Companies (2022-2030) ($MN)
  • Table 39 Global Minimal Residual Disease Market Outlook, By Contract Research Organizations (CROs) (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.